Načítá se...
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
BACKGROUND: The pathological complete response (pCR) after neoadjuvant chemotherapy is a surrogate marker for a favorable prognosis in breast cancer patients. Factors capable of predicting a pCR, such as the proliferation marker Ki67, may therefore help improve our understanding of the drug response...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3262864/ https://ncbi.nlm.nih.gov/pubmed/22081974 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-486 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|